Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amber Patterson

Allergy & Immunology Findlay, OH Medical Doctor

NPI 1104082957 CMS profile 622278

825 S Main St, Findlay, OH 45840

Open in the dashboard

General payments

$128,268

386 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$54,786 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Amber Patterson of Findlay, OH is reported in the CMS Open Payments database as having received $128,268 across 386 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $54,786 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $58,456 137
2024 General $20,642 69
2023 General $4,902 108
2022 General $6,370 10
2021 General $9,428 12
2020 General $13,036 16
2019 General $15,433 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amber Patterson
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Amber Patterson were reported at $58,456. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Amber Patterson Allergy & Immunology median Middle half National median
2019 $15,433 $594 $163–$1,512 $163
2020 $13,036 $426 $106–$1,233 $114
2021 $9,428 $638 $157–$1,708 $132
2022 $6,370 $790 $205–$1,961 $149
2023 $4,902 $852 $220–$2,147 $160
2024 $20,642 $865 $203–$2,267 $164
2025 $58,456 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $62,942 83 payments
  2. ARS Pharmaceuticals Operations, Inc. $39,728 37 payments
  3. Shire North American Group Inc $12,166 24 payments
  4. OptiNose US, Inc. $3,314 16 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $2,679 20 payments
  6. kaleo, Inc. $1,859 12 payments
  7. Amgen Inc. $854 19 payments
  8. AstraZeneca Pharmaceuticals LP $811 31 payments
  9. Regeneron Healthcare Solutions, Inc. $602 21 payments
  10. Pfizer Inc. $486 32 payments
  11. Other $2,827 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $94,912 37 payments
  2. Travel and Lodging $16,426 35 payments
  3. Food and Beverage $9,359 298 payments
  4. Consulting Fee $7,383 13 payments
  5. Education $188 3 payments
Products named General payments · program years 2019–2025
  1. NUCALA Immunology $47,977 59 payments
  2. NEFFY $39,728 37 payments
  3. HYQVIA $14,510 28 payments
  4. NUCALA Respiratory $9,059 10 payments
  5. Xhance $3,314 16 payments
  6. AUVI-Q $1,818 10 payments
  7. DUPIXENT Immunology $860 25 payments
  8. TEZSPIRE Inflammation $820 18 payments
  9. DUPIXENT Inflammation And Immunology $469 15 payments
  10. TEZSPIRE Respiratory $341 15 payments
  11. Other $3,877 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

229

Median for Allergy/ Immunology: 449

Drug cost

$141,024

Median for Allergy/ Immunology: $169,700

Branded share of claims

22.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucala Mepolizumab Brand 21 $84,212
Xolair Omalizumab Brand 19 $44,561
Breo Ellipta Fluticasone/Vilanterol Brand 12 $5,798
Epinephrine Generic 13 $3,315
Ipratropium Bromide Generic 33 $1,270
Montelukast Sodium Generic 91 $1,135
Fluticasone Propionate Generic 24 $469
Azelastine Hcl Generic 16 $263

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$40,650

Medicare's payments for the services billed

Medicare patients

107

Average age 73

Services billed

4,071

83 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 64%
Osteoporosis 23%
Diabetes 21%
COPD 20%
Chronic kidney disease 18%
Depression 18%
Ischemic heart disease 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $19,197
$19,197 21 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $210
  • SANOFI-AVENTIS U.S. LLC $77
  • GENZYME CORPORATION $58
$345 — —
Orladeyo
  • BioCryst US Sales Co., LLC $147
$147 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $95
  • Amgen Inc. $41
$136 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

386 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record